Europe Sjs Ten Treatment Market
Taille du marché en milliards USD
TCAC :
% 
USD
1,686.96 Million
USD
2,737.34 Million
2022
2030
 Période de prévision |
2023 –2030 |
 Taille du marché (année de référence) |
USD 1,686.96 Million |
 Taille du marché (année de prévision) |
USD 2,737.34 Million |
 TCAC |
% |
| Principaux acteurs du marché |
|
Marché européen du traitement SJS/TEN, par traitement (médicaments, soins de soutien, hospitalisation, isolement, pommades et autres), diagnostic (examen physique, biopsie cutanée , antécédents médicaux, analyse sanguine, cultures et autres), cause (traitement spécifique, infection et autres), voie d'administration (orale, parentérale, topique et autres), type de médicament (de marque et générique), domaine thérapeutique (thérapie combinée et monothérapie), type de patient (gériatrique, adulte et pédiatrique), utilisateur final (hôpitaux, cliniques spécialisées, centre de chirurgie ambulatoire, cadre de soins à domicile et autres), canal de distribution (pharmacies de détail, appel d'offres direct et autres) - Tendances et prévisions de l'industrie jusqu'en 2030.
Analyse et perspectives du marché européen du traitement du syndrome de Stevens-Johnson (SJS) et du syndrome de tétanos (TEN)
Le marché du traitement du syndrome de Stevens-Johnson (SJS) et de la nécrolyse épidermique toxique (NET) est relativement restreint en raison de la rareté de ces maladies.
Le marché européen du traitement du SJS/TEN est dominé par les médicaments, car ils constituent la principale forme de traitement de ces pathologies. Les corticostéroïdes, les immunoglobulines intraveineuses (IVIG) et les antibiotiques sont les médicaments les plus couramment utilisés dans le traitement du SJS/TEN.
Le marché européen du traitement SJS/TEN devrait connaître une croissance du marché au cours de la période de prévision de 2023 à 2030. Data Bridge Market Research analyse que le marché croît avec un TCAC de 6,4 % au cours de la période de prévision de 2023 à 2030 et devrait atteindre 2 737,34 millions USD d'ici 2030 contre 1 686,96 millions USD en 2022.
Le rapport sur le marché européen du traitement SJS/TEN fournit des détails sur la part de marché, les nouveaux développements et l'analyse du pipeline de produits, l'impact des acteurs du marché national et localisé, analyse les opportunités en termes de poches de revenus émergentes, de changements dans la réglementation du marché, d'approbations de produits, de décisions stratégiques, de lancements de produits, d'expansions géographiques et d'innovations technologiques sur le marché. Pour comprendre l'analyse et le scénario du marché, contactez-nous pour un briefing d'analyste. Notre équipe vous aidera à créer une solution d'impact sur les revenus pour atteindre votre objectif souhaité. L'évolutivité et l'expansion commerciale des unités de vente au détail dans les pays en développement de diverses régions et le partenariat avec les fournisseurs pour une distribution sûre de machines et de produits pharmaceutiques sont les principaux moteurs qui ont propulsé la demande du marché au cours de la période de prévision.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Années historiques |
2021 (personnalisable de 2015 à 2020) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD |
|
Segments couverts |
Traitement (médicaments, soins de soutien, hospitalisation, isolement, pommades et autres), diagnostic (examen physique, biopsie cutanée, antécédents médicaux, analyse sanguine, cultures et autres), cause (traitement spécifique, infection et autres), voie d'administration (orale, parentérale, topique et autres), type de médicament (de marque et générique), domaine thérapeutique (thérapie combinée et monothérapie), type de patient (gériatrique, adulte et pédiatrique), utilisateur final (hôpitaux, cliniques spécialisées, centre de chirurgie ambulatoire, cadre de soins à domicile et autres), canal de distribution (pharmacies de détail, appel d'offres direct et autres) |
|
Pays couverts |
Royaume-Uni, France, Allemagne, Italie, Russie, Espagne, Pays-Bas, Danemark, Suisse, Suède, Pologne, Norvège, Finlande, Belgique, Turquie, Reste de l'Europe |
|
Acteurs du marché couverts |
3M (États-Unis), Cardinal Health (États-Unis), BD (États-Unis), Smith + Nephew (Royaume-Uni), Novartis AG (Suisse), Amneal Pharmaceuticals LLC. (États-Unis), Amgen Inc. (États-Unis), Pfizer Inc. (États-Unis), Colgate-Palmolive Company (États-Unis), Merck & Co., Inc. (États-Unis), Mölnlycke Health Care AB. (Suède), Xttrium Laboratories (États-Unis), Schülke & Mayr GmbH (Allemagne), ICPA Health Products Ltd (Inde), Purdue Pharma LP (États-Unis), eugia (filiale d'Aurobindo Pharma) et AdvaCare Pharma (États-Unis) entre autres |
Définition du marché
Le syndrome de Stevens-Johnson (SSJ) et la nécrolyse épidermique toxique (NET) sont des affections cutanées rares mais potentiellement mortelles qui résultent généralement de réactions graves aux médicaments. Ces affections provoquent la séparation de la couche supérieure de la peau des couches inférieures, ce qui entraîne des cloques et des plaies douloureuses qui peuvent couvrir une grande partie du corps. Le SSJ affecte une petite partie de la peau, tandis que la NET affecte une plus grande partie de la peau.
La définition du traitement du SJS/TEN fait référence aux produits et services conçus pour gérer et traiter ces pathologies. Il existe sur le marché des médicaments, des thérapies et d'autres traitements qui peuvent aider à soulager les symptômes du SJS/TEN et à améliorer la qualité de vie des patients. Le marché des médicaments pour le traitement du SJS/TEN comprend un certain nombre de médicaments utilisés pour soulager les symptômes et traiter la cause sous-jacente.
Dynamique du marché européen du traitement du syndrome de Stevens-Johnson (SJS) et du syndrome de neutrophiles (TEN)
Cette section traite de la compréhension des moteurs, des avantages, des contraintes et des défis du marché. Tout cela est discuté en détail ci-dessous :
Conducteurs
-
Augmentation de la prévalence et de l'incidence du syndrome de Stevens-Johnson/nécrolyse épidermique toxique
Le syndrome de Stevens-Johnson (SSJ) et la nécrolyse épidermique toxique (NET) sont des maladies graves et potentiellement mortelles qui touchent la peau et les muqueuses. Le SSJ et la NET sont considérés comme les deux extrémités du spectre de la maladie, le SSJ étant la forme la plus légère et la NET la forme la plus grave. Une caractéristique de ces maladies est la séparation de l'épiderme (la couche externe de la peau) du derme (la couche située sous la peau) en raison d'une forte réaction immunitaire.
Le syndrome de Stevens-Johnson (SSJ) et la nécrolyse épidermique toxique (NET) sont des maladies cutanées rares mais graves caractérisées par la séparation de l'épiderme et du derme. L'incidence du SSJ/NET a été estimée à environ 1 par million de personnes par an. Cependant, ces dernières années, l'incidence et la prévalence du SSJ/NET ont suscité une inquiétude croissante.
-
Progrès dans le développement de médicaments pour le traitement du syndrome de Stevens-Johnson/TEN
Le syndrome de Stevens-Johnson (SSJ) et la nécrolyse épidermique toxique (NET) sont des maladies graves et potentiellement mortelles qui nécessitent un traitement rapide et agressif. Bien qu'il n'existe actuellement aucun médicament ou traitement spécifique capable de guérir le SSJ/NET, les progrès dans le développement de médicaments ont conduit à de meilleures stratégies de traitement et à de meilleurs résultats pour les patients concernés. Mais divers essais cliniques sont en cours pour le développement de médicaments pour le traitement du SSJ/NET.
Retenue
-
Coût élevé associé au traitement du syndrome de Stevens-Johnson/nécrolyse épidermique toxique
L’une des principales raisons pour lesquelles le traitement du syndrome de Stevens-Johnson/nécrolyse épidermique toxique est coûteux est la nécessité d’un traitement intensif et à long terme. Les patients atteints de ce syndrome doivent souvent être hospitalisés dans des unités spécialisées pour les brûlés, où ils reçoivent des soins 24 heures sur 24 par une équipe de professionnels de la santé comprenant des dermatologues, des ophtalmologues et des spécialistes des soins intensifs. L’hospitalisation peut durer plusieurs semaines et, dans les cas graves, même des mois. Cela peut entraîner des factures d’hôpital élevées et d’autres coûts connexes tels que le transport, l’hébergement et les repas.
Opportunité
-
Développement d'un traitement efficace et sûr pour le syndrome de Stevens-Johnson (SJS) et la névralgie tétanique (NET)
La transplantation de cellules souches est une nouvelle approche qui vise à remplacer la peau et les muqueuses endommagées par des tissus sains. La transplantation autologue de cellules souches, où les cellules souches sont prélevées sur la peau du patient et mises en culture avant d'être réimplantées dans la zone endommagée, a montré des résultats prometteurs dans de petites études.
Défi
- Réglementation gouvernementale stricte pour l'approbation d'un traitement pour le syndrome de Stevens-Johnson/nécrolyse épidermique toxique
Les réglementations gouvernementales strictes pour l'approbation des traitements SJS/TEN sont liées au processus complexe et rigoureux que les sociétés pharmaceutiques et leurs médicaments doivent suivre pour obtenir l'approbation d'un traitement SJS/TEN auprès d'agences de réglementation telles que la Food and Drug Administration (FDA) des États-Unis ou l'Agence européenne des médicaments (EMA).
Le processus d’approbation d’un nouveau médicament implique généralement plusieurs étapes d’essais cliniques sur l’homme pour évaluer la sécurité et l’efficacité du médicament.
Développements récents
- En juin 2020, BD, l'une des principales entreprises européennes de technologie médicale, a annoncé avoir finalisé l'acquisition de Straub Medical AG, une société privée. Avec cette acquisition, l'entreprise a ajouté l'expertise et l'expérience précieuses de Straub Medical AG et a élargi son portefeuille de produits. Cela aidera l'entreprise à se développer et à croître sur le marché.
- En janvier 2019, Mölnlycke Health Care AB a acquis MandJ Airlaid Products A/S pour renforcer ses capacités en matière de soins des plaies. Dans le cadre de cette acquisition, MandJ et ses employés feront partie intégrante de Mölnlycke. Cette acquisition améliorera la sécurité d'approvisionnement de Mölnlycke en matériaux airlaid nécessaires à la production de pansements avancés et contribuera à la croissance de l'activité de soins des plaies en accélérant l'innovation et le développement de produits dans les produits existants et futurs. Cela aidera l'entreprise à se développer et à croître sur le marché.
Portée du marché européen du traitement SJS/TEN
Le marché européen du traitement SJS/TEN est classé en neuf segments notables en fonction du traitement, du diagnostic, de la cause, de la voie d'administration, du type de médicament, du type de thérapie, du type de patient, de l'utilisateur final et du canal de distribution. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et la différence entre vos marchés cibles.
Le marché européen du traitement SJS/TEN est classé en neuf segments notables en fonction du traitement, du diagnostic, de la cause, de la voie d’administration, du type de médicament, du type de thérapie, du type de patient, de l’utilisateur final et du canal de distribution.
Traitement
- Médicaments
- Soins de soutien
- Pommades
- Hospitalisation
- Isolement
- Autres
Sur la base du traitement, le marché européen du traitement SJS/TEN est segmenté en médicaments, soins de soutien, hospitalisation, isolement, pommades et autres.
Diagnostic
- Examen physique
- Antécédents médicaux
- Biopsie cutanée
- Analyse de sang
- Cultures
- Autres
Sur la base du diagnostic, le marché européen du traitement SJS/TEN est segmenté en examen physique, biopsie cutanée, antécédents médicaux, analyse de sang, cultures et autres.
Cause
- Traitement spécifique
- Infection
- Autres
Sur la base de la cause, le marché européen du traitement SJS/TEN est segmenté en traitement spécifique, infection et autres.
Voie d'administration
- Oral
- Parentérale
- Topique
- Autres
Sur la base de la voie d'administration, le marché européen du traitement SJS/TEN est segmenté en voie orale, parentérale, topique et autres.
Type de médicament
- De marque
- Générique
Sur la base du type de médicament, le marché européen du traitement SJS/TEN est segmenté en médicaments de marque et génériques.
Type de thérapie
- Monothérapie
- Thérapie combinée
Sur la base du type de thérapie, le marché européen du traitement SJS/TEN est segmenté en thérapie combinée et monothérapie.
Type de patient
- Pédiatrique
- Adulte
- Gériatrie
Sur la base du type de patient, le marché européen du traitement SJS/TEN est segmenté en gériatrique, adulte et pédiatrique.
Utilisateur final
- Hôpitaux
- Cliniques spécialisées
- Centre de chirurgie ambulatoire
- Cadre de soins à domicile
- Autres
Sur la base de l'utilisateur final, le marché européen du traitement SJS/TEN est segmenté en hôpitaux, cliniques spécialisées, centres de chirurgie ambulatoire, soins à domicile et autres.
Canal de distribution
- Appels d'offres directs
- Pharmacies de détail
- Autres
Sur la base du canal de distribution, le marché européen du traitement SJS/TEN est segmenté en pharmacies de détail, appels d'offres directs et autres.
Analyse/perspectives régionales du marché du traitement SJS/TEN en Europe
Le marché européen du traitement SJS/TEN est classé en neuf segments notables en fonction du traitement, du diagnostic, de la cause, de la voie d’administration, du type de médicament, du type de thérapie, du type de patient, de l’utilisateur final et du canal de distribution.
Les pays couverts dans ce rapport de marché sont le Royaume-Uni, la France, l'Allemagne, l'Italie, la Russie, l'Espagne, les Pays-Bas, le Danemark, la Suisse, la Suède, la Pologne, la Norvège, la Finlande, la Belgique, la Turquie et le reste de l'Europe.
L'Allemagne devrait dominer en raison d'une augmentation de la production de traitements SJS/TEN et de la demande croissante des marchés émergents, ainsi que de l'expansion des industries de la santé.
La section par pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie des pays, les actes réglementaires et les tarifs d'importation et d'exportation sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques européennes et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, ainsi que l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Paysage concurrentiel et analyse des parts de marché du traitement SJS/TEN en Europe
Le paysage concurrentiel du marché européen du traitement SJS/TEN fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les approbations de produits, la largeur et la portée du produit, la domination des applications et la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise sur le marché européen du traitement SJS/TEN.
Français Certains des principaux acteurs opérant sur le marché européen du traitement SJS/TEN sont 3M (États-Unis), Cardinal Health (États-Unis), BD (États-Unis), Smith + Nephew (Royaume-Uni), Novartis AG (Suisse), Amneal Pharmaceuticals LLC. (États-Unis), Amgen Inc. (États-Unis), Pfizer Inc. (États-Unis), Colgate-Palmolive Company (États-Unis), Merck & Co., Inc. (États-Unis), Mölnlycke Health Care AB. (Suède), Xttrium Laboratories (États-Unis), Schülke & Mayr GmbH (Allemagne), ICPA Health Products Ltd (Inde), Purdue Pharma LP (États-Unis), eugia (filiale d'Aurobindo Pharma) et AdvaCare Pharma (États-Unis), entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE SJS/TEN TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TREATMENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 KEY TRENDS
4.2 COST OF TREATMENT
4.3 KEY PLAYERS STRATEGIES
4.4 LONG TERM GROWTH APPROACH
5 EPIDEMIOLOGY
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.2 DEMOGRAPHIC TRENDS
6.3 PATIENT FLOW DIAGRAM
6.4 KEY PRICING STRATEGIES
6.5 KEY PATIENT ENROLLMENT STRATEGIES
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE AND INCIDENCE OF SJS/TEN
7.1.2 ADVANCES IN DRUG DEVELOPMENT FOR SJS/TEN TREATMENT
7.1.3 INCREASING AWARENESS ABOUT THE RARE DISEASE SJS/TEN
7.1.4 GOVERNMENT INITIATIVES FOR SJS/TEN TREATMENT
7.2 RESTRAINTS
7.2.1 HIGH COST ASSOCIATED WITH THE TREATMENT OF SJS/TEN
7.2.2 LIMITED AVAILABILITY OF SPECIALIZED CARE FOR SJS/TEN TREATMENT
7.3 OPPORTUNITIES
7.3.1 DEVELOPING EFFECTIVE AND SAFE TREATMENT FOR SJS/TEN
7.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES FOR SJS/TEN TREATMENT
7.4 CHALLENGES
7.4.1 STRINGENT GOVERNMENT REGULATIONS FOR APPROVAL OF TREATMENT FOR SJS/TEN
7.4.2 LONG TERM COMPLICATIONS AND ADVERSE EFFECTS OF MEDICATIONS USED IN THE SJS/TEN TREATMENT
8 EUROPE SJS/TEN TREATMENT MARKET, BY TREATMENT
8.1 OVERVIEW
8.2 MEDICATIONS
8.2.1 ANTIHISTAMINES
8.2.1.1 HYDROXYZINE
8.2.1.2 FEXOFENADINE
8.2.2 CORTICOSTEROID
8.2.2.1 DEXAMETHASONE
8.2.2.2 PREDNISOLONE
8.2.2.3 METHYLPREDNISOLONE
8.2.2.4 HYDROCORTISONE
8.2.2.5 OTHERS
8.2.3 ANTIBIOTICS
8.2.3.1 NAFCILLIN
8.2.3.2 GENTAMICIN
8.2.3.3 OTHERS
8.2.4 ANALGESICS
8.2.4.1 MORPHINE
8.2.4.2 FENTANYL CITRATE
8.2.4.3 OTHERS
8.2.5 ANTICOAGULANTS
8.2.6 ANTISEPTICS
8.2.6.1 CHLORHEXIDINE GLUCONATE
8.2.6.1.1 PERIOGARD
8.2.6.1.2 PERIDEX
8.2.6.1.3 AVAGARD
8.2.6.1.4 HIBICLENS
8.2.6.1.5 OTHERS
8.2.6.2 OCTENISEPT
8.2.6.3 POLYHEXANIDE SOLUTIONS
8.2.6.4 OTHERS
8.2.7 INTRAVENOUS IMMUNOGLOBULIN
8.2.8 CYCLOSPORINE
8.2.8.1 NEORAL
8.2.8.2 SANDIMMUNE
8.2.8.3 OTHERS
8.2.9 TUMOR NECROSIS FACTOR-ALPHA (TNF-Α)‒BLOCKING AGENT (ETANERCEPT)
8.2.10 OTHER TREATMENT
8.2.10.1 CYCLOPHOSPHAMIDE
8.2.10.2 N-ACETYLCYSTEINE
8.2.10.3 MONOCLONAL ANTIBODIES
8.2.10.4 THALIDOMIDE
8.3 SUPPORT CARE
8.3.1 INTRAVENOUS (IV) FLUID AND ELECTROLYTES
8.3.2 PAIN MANAGEMENT
8.3.2.1 LIDOCAINE
8.3.2.2 OTHERS
8.3.3 NUTRITION SUPPORT
8.3.4 ORAL CARE
8.3.5 PLASMAPHERESIS
8.3.6 BANDAGES
8.3.6.1 BIOLOGICAL DRESSING
8.3.6.1.1 ALLOGRAFT
8.3.6.1.2 XENOGRAFT
8.3.6.1.3 HOMOGRAFT
8.3.6.1.4 OTHERS
8.3.6.2 BIOSYNTHETIC DRESSING
8.3.6.3 SILVER IMPREGNATED DRESSING
8.4 HOSPITALIZATION
8.5 ISOLATION
8.6 OINTMENTS
8.6.1 BENZOCAINE
8.6.2 AMERICAINE
8.6.3 ANBESOL
8.6.4 CHIGGEREX PLUS
8.6.5 OTHERS
8.7 OTHERS
9 EUROPE SJS/TEN TREATMENT MARKET, BY DIAGNOSIS
9.1 OVERVIEW
9.2 PHYSICAL EXAM
9.3 SKIN BIOPSY
9.4 MEDICAL HISTORY
9.5 BLOOD TEST
9.5.1 COMPLETE BLOOD COUNT
9.5.2 ERYTHROCYTE SEDIMENTATION RATE
9.5.3 COAGULATION STUDIES
9.5.4 UREA AND ELECTROLYTES
9.5.5 LIVER FUNCTION TEST
9.6 CULTURES
9.7 OTHERS
10 EUROPE SJS/TEN TREATMENT MARKET, BY CAUSE
10.1 OVERVIEW
10.2 SPECIFIC TREATMENT
10.3 INFECTION
10.4 OTHERS
11 EUROPE SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.3 PARENTERAL
11.3.1 INTRAVENOUS
11.3.2 SUBCUTANEOUS
11.3.3 OTHERS
11.4 TOPICAL
11.4.1 OINTMENTS
11.4.2 SOLUTION
11.4.3 CREAMS
11.4.4 OTHERS
11.5 OTHERS
12 EUROPE SJS/TEN TREATMENT MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 BRANDED
12.2.1 NEORAL
12.2.2 SANDIMMUNE
12.2.3 VISTARIL
12.2.4 DURAMORPH
12.2.5 FENTORA
12.2.6 ENBREL
12.2.7 OTHERS
12.3 GENERIC
13 EUROPE SJS/TEN TREATMENT MARKET, BY THERAPY TYPE
13.1 OVERVIEW
13.2 COMBINATION THERAPY
13.3 MONOTHERAPY
14 EUROPE SJS/TEN TREATMENT MARKET, BY PATIENT TYPE
14.1 OVERVIEW
14.2 GERIATRIC
14.2.1 FEMALE
14.2.2 MALE
14.3 ADULT
14.3.1 FEMALE
14.3.2 MALE
14.4 PEDIATRIC
15 EUROPE SJS/TEN TREATMENT MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECIALTY CLINICS
15.4 AMBULATORY SURGICAL CENTER
15.5 HOMECARE SETTING
15.6 OTHERS
16 EUROPE SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 RETAIL PHARMACIES
16.2.1 HOSPITAL ASSOCIATED PHARMACIES
16.2.2 DRUG STORE
16.2.3 ONLINE PHARMACIES
16.3 DIRECT TENDERS
16.4 OTHERS
17 EUROPE SJS/TEN TREATMENT MARKET, BY REGION
17.1 EUROPE
17.1.1 GERMANY
17.1.2 FRANCE
17.1.3 U.K.
17.1.4 ITALY
17.1.5 SPAIN
17.1.6 RUSSIA
17.1.7 TURKEY
17.1.8 BELGIUM
17.1.9 DENMARK
17.1.10 NETHERLANDS
17.1.11 SWITZERLAND
17.1.12 SWEDEN
17.1.13 POLAND
17.1.14 NORWAY
17.1.15 FINLAND
17.1.16 REST OF EUROPE
18 EUROPE SJS/TEN TREATMENT MARKET, COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: EUROPE
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 PFIZER INC.
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENT
20.2 NOVARTIS AG
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENT
20.3 MERCK & CO., INC.
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENT
20.4 AMNEAL PHARMACEUTICAL LLC.
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENT
20.5 AMGEN INC.
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 PRODUCT PORTFOLIO
20.5.4 RECENT DEVELOPMENT
20.6 ADVACARE PHARMA
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENT
20.7 BD
20.7.1 COMPANY SNAPSHOT
20.7.2 REVENUE ANALYSIS
20.7.3 PRODUCT PORTFOLIO
20.7.4 RECENT DEVELOPMENT
20.8 CARDINAL HEALTH
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENT
20.9 COLGATE-PALMOLIVE COMPANY
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORTFOLIO
20.9.4 RECENT DEVELOPMENT
20.1 EUGIA (SUBSIDIARY OF AUROBINDO PHARMA)
20.10.1 COMPANY SNAPSHOT
20.10.2 REVENUE ANALYSIS
20.10.3 PRODUCT PORTFOLIO
20.10.4 RECENT DEVELOPMENT
20.11 ICPA HEALTH PRODUCTS LTD
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENT
20.12 3M
20.12.1 COMPANY SNAPSHOT
20.12.2 REVENUE ANALYSIS
20.12.3 PRODUCT PORTFOLIO
20.12.4 RECENT DEVELOPMENT
20.13 MOLNLYCKE HEALTH CARE AB.
20.13.1 COMPANY SNAPSHOT
20.13.2 PRODUCT PORTFOLIO
20.13.3 RECENT DEVELOPMENT
20.14 PURDUE PHARMA L.P.
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENT
20.15 SCHULKE & MAYR GMBH
20.15.1 COMPANY SNAPSHOT
20.15.2 PRODUCT PORTFOLIO
20.15.3 RECENT DEVELOPMENT
20.16 SMITH + NEPHEW
20.16.1 COMPANY SNAPSHOT
20.16.2 REVENUE ANALYSIS
20.16.3 PRODUCT PORTFOLIO
20.16.4 RECENT DEVELOPMENT
20.17 XTTRIUM LABORATORIES
20.17.1 COMPANY SNAPSHOT
20.17.2 PRODUCT PORTFOLIO
20.17.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
Liste des tableaux
TABLE 1 EUROPE SJS/TEN TREATMENT MARKET, PATENT ANALYSIS
TABLE 2 EUROPE SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 3 EUROPE MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 EUROPE MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 5 EUROPE ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 6 EUROPE CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 7 EUROPE ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 8 EUROPE ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 9 EUROPE ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 10 EUROPE CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 11 EUROPE CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 12 EUROPE OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 13 EUROPE SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 EUROPE SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 15 EUROPE PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 16 EUROPE BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 17 EUROPE BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 18 EUROPE HOSPITALIZATION IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 EUROPE ISOLATION IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 EUROPE OINTMENTS IN JS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 EUROPE OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 22 EUROPE OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 EUROPE SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 24 EUROPE PHYSICAL EXAM IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 EUROPE SKIN BIOPSY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 EUROPE MEDICAL HISTORY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 EUROPE BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 EUROPE BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 29 EUROPE CULTURES IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 EUROPE OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 EUROPE SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 32 EUROPE SPECIFIC TREATMENT IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 EUROPE INFECTION IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 EUROPE OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 EUROPE SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 36 EUROPE ORAL IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 EUROPE PARENTERAL IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 EUROPE PARENTERAL IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 39 EUROPE TOPICAL IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 EUROPE TOPICAL IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 41 EUROPE OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 EUROPE SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 43 EUROPE BRANDED IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 EUROPE BRANDED IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 45 EUROPE GENERIC IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 EUROPE SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 47 EUROPE COMBINATION THERAPY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 EUROPE MONOTHERAPY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 49 EUROPE SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 50 EUROPE GERAITRIC IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 EUROPE GERIATRIC IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 52 EUROPE ADULT IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 EUROPE ADULT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 54 EUROPE PEDIATRIC IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 EUROPE SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 56 EUROPE HOSPITALS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 EUROPE SPECIALTY CLINICS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 58 EUROPE AMBULATORY SURGICAL CENTER IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 59 EUROPE HOMECARE SETTING IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 60 EUROPE OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 61 EUROPE SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 62 EUROPE RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 63 EUROPE RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 64 EUROPE DIRECT TENDERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 65 EUROPE OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 66 EUROPE SJS/TEN TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 67 EUROPE SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 68 EUROPE MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 69 EUROPE ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 70 EUROPE CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 71 EUROPE ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 72 EUROPE ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 73 EUROPE ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 74 EUROPE CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 75 EUROPE CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 76 EUROPE OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 77 EUROPE SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 78 EUROPE PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 79 EUROPE BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 80 EUROPE BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 81 EUROPE OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 82 EUROPE SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 83 EUROPE BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 84 EUROPE SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 85 EUROPE SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 86 EUROPE PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 87 EUROPE TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 88 EUROPE SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 89 EUROPE BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 90 EUROPE SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 91 EUROPE SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 92 EUROPE GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 93 EUROPE ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 94 EUROPE SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 95 EUROPE SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 96 EUROPE RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 97 GERMANY SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 98 GERMANY MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 99 GERMANY ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 100 GERMANY CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 101 GERMANY ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 102 GERMANY ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 103 GERMANY ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 104 GERMANY CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 105 GERMANY CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 106 GERMANY OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 107 GERMANY SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 108 GERMANY PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 109 GERMANY BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 110 GERMANY BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 111 GERMANY OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 112 GERMANY SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 113 GERMANY BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 114 GERMANY SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 115 GERMANY SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 116 GERMANY PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 117 GERMANY TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 118 GERMANY SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 119 GERMANY BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 120 GERMANY SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 121 GERMANY SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 122 GERMANY GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 123 GERMANY ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 124 GERMANY SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 125 GERMANY SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 126 GERMANY RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 127 FRANCE SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 128 FRANCE MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 129 FRANCE ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 130 FRANCE CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 131 FRANCE ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 132 FRANCE ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 133 FRANCE ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 134 FRANCE CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 135 FRANCE CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 136 FRANCE OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 137 FRANCE SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 138 FRANCE PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 139 FRANCE BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 140 FRANCE BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 141 FRANCE OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 142 FRANCE SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 143 FRANCE BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 144 FRANCE SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 145 FRANCE SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 146 FRANCE PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 147 FRANCE TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 148 FRANCE SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 149 FRANCE BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 150 FRANCE SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 151 FRANCE SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 152 FRANCE GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 153 FRANCE ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 154 FRANCE SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 155 FRANCE SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 156 FRANCE RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 157 U.K. SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 158 U.K. MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 159 U.K. ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 160 U.K. CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 161 U.K. ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 162 U.K. ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 163 U.K. ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 164 U.K. CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 165 U.K. CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 166 U.K. OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 167 U.K. SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 168 U.K. PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 169 U.K. BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 170 U.K. BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 171 U.K. OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 172 U.K. SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 173 U.K. BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 174 U.K. SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 175 U.K. SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 176 U.K. PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 177 U.K. TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 178 U.K. SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 179 U.K. BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 180 U.K. SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 181 U.K. SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 182 U.K. GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 183 U.K. ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 184 U.K. SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 185 U.K. SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 186 U.K. RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 187 ITALY SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 188 ITALY MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 189 ITALY ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 190 ITALY CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 191 ITALY ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 192 ITALY ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 193 ITALY ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 194 ITALY CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 195 ITALY CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 196 ITALY OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 197 ITALY SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 198 ITALY PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 199 ITALY BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 200 ITALY BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 201 ITALY OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 202 ITALY SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 203 ITALY BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 204 ITALY SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 205 ITALY SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 206 ITALY PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 207 ITALY TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 208 ITALY SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 209 ITALY BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 210 ITALY SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 211 ITALY SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 212 ITALY GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 213 ITALY ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 214 ITALY SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 215 ITALY SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 216 ITALY RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 217 SPAIN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 218 SPAIN MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 219 SPAIN ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 220 SPAIN CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 221 SPAIN ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 222 SPAIN ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 223 SPAIN ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 224 SPAIN CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 225 SPAIN CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 226 SPAIN OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 227 SPAIN SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 228 SPAIN PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 229 SPAIN BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 230 SPAIN BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 231 SPAIN OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 232 SPAIN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 233 SPAIN BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 234 SPAIN SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 235 SPAIN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 236 SPAIN PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 237 SPAIN TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 238 SPAIN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 239 SPAIN BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 240 SPAIN SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 241 SPAIN GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 242 SPAIN ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 243 SPAIN SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 244 SPAIN SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 245 SPAIN RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 246 RUSSIA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 247 RUSSIA MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 248 RUSSIA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 249 RUSSIA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 250 RUSSIA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 251 RUSSIA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 252 RUSSIA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 253 RUSSIA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 254 RUSSIA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 255 RUSSIA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 256 RUSSIA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 257 RUSSIA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 258 RUSSIA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 259 RUSSIA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 260 RUSSIA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 261 RUSSIA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 262 RUSSIA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 263 RUSSIA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 264 RUSSIA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 265 RUSSIA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 266 RUSSIA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 267 RUSSIA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 268 RUSSIA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 269 RUSSIA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 270 RUSSIA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 271 RUSSIA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 272 RUSSIA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 273 RUSSIA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 274 RUSSIA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 275 RUSSIA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 276 TURKEY SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 277 TURKEY MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 278 TURKEY ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 279 TURKEY CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 280 TURKEY ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 281 TURKEY ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 282 TURKEY ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 283 TURKEY CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 284 TURKEY CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 285 TURKEY OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 286 TURKEY SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 287 TURKEY PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 288 TURKEY BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 289 TURKEY BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 290 TURKEY OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 291 TURKEY SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 292 TURKEY BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 293 TURKEY SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 294 TURKEY SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 295 TURKEY PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 296 TURKEY TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 297 TURKEY SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 298 TURKEY BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 299 TURKEY SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 300 TURKEY SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 301 TURKEY GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 302 TURKEY ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 303 TURKEY SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 304 TURKEY SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 305 TURKEY RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 306 BELGIUM SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 307 BELGIUM MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 308 BELGIUM ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 309 BELGIUM CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 310 BELGIUM ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 311 BELGIUM ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 312 BELGIUM ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 313 BELGIUM CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 314 BELGIUM CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 315 BELGIUM OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 316 BELGIUM SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 317 BELGIUM PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 318 BELGIUM BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 319 BELGIUM BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 320 BELGIUM OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 321 BELGIUM SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 322 BELGIUM BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 323 BELGIUM SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 324 BELGIUM SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 325 BELGIUM PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 326 BELGIUM TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 327 BELGIUM SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 328 BELGIUM BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 329 BELGIUM SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 330 BELGIUM SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 331 BELGIUM GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 332 BELGIUM ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 333 BELGIUM SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 334 BELGIUM SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 335 BELGIUM RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 336 DENMARK SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 337 DENMARK MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 338 DENMARK ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 339 DENMARK CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 340 DENMARK ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 341 DENMARK ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 342 DENMARK ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 343 DENMARK CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 344 DENMARK CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 345 DENMARK OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 346 DENMARK SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 347 DENMARK PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 348 DENMARK BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 349 DENMARK BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 350 DENMARK OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 351 DENMARK SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 352 DENMARK BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 353 DENMARK SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 354 DENMARK SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 355 DENMARK PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 356 DENMARK TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 357 DENMARK SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 358 DENMARK BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 359 DENMARK SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 360 DENMARK SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 361 DENMARK GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 362 DENMARK ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 363 DENMARK SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 364 DENMARK SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 365 DENMARK RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 366 NETHERLANDS SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 367 NETHERLANDS MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 368 NETHERLANDS ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 369 NETHERLANDS CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 370 NETHERLANDS ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 371 NETHERLANDS ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 372 NETHERLANDS ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 373 NETHERLANDS CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 374 NETHERLANDS CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 375 NETHERLANDS OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 376 NETHERLANDS SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 377 NETHERLANDS PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 378 NETHERLANDS BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 379 NETHERLANDS BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 380 NETHERLANDS OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 381 NETHERLANDS SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 382 NETHERLANDS BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 383 NETHERLANDS SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 384 NETHERLANDS SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 385 NETHERLANDS PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 386 NETHERLANDS TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 387 NETHERLANDS SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 388 NETHERLANDS BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 389 NETHERLANDS SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 390 NETHERLANDS SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 391 NETHERLANDS GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 392 NETHERLANDS ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 393 NETHERLANDS SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 394 NETHERLANDS SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 395 NETHERLANDS RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 396 SWITZERLAND SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 397 SWITZERLAND MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 398 SWITZERLAND ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 399 SWITZERLAND CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 400 SWITZERLAND ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 401 SWITZERLAND ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 402 SWITZERLAND ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 403 SWITZERLAND CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 404 SWITZERLAND CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 405 SWITZERLAND OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 406 SWITZERLAND SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 407 SWITZERLAND PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 408 SWITZERLAND BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 409 SWITZERLAND BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 410 SWITZERLAND OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 411 SWITZERLAND SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 412 SWITZERLAND BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 413 SWITZERLAND SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 414 SWITZERLAND SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 415 SWITZERLAND PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 416 SWITZERLAND TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 417 SWITZERLAND SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 418 SWITZERLAND BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 419 SWITZERLAND SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 420 SWITZERLAND SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 421 SWITZERLAND GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 422 SWITZERLAND ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 423 SWITZERLAND SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 424 SWITZERLAND SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 425 SWITZERLAND RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 426 SWEDEN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 427 SWEDEN MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 428 SWEDEN ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 429 SWEDEN CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 430 SWEDEN ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 431 SWEDEN ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 432 SWEDEN ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 433 SWEDEN CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 434 SWEDEN CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 435 SWEDEN OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 436 SWEDEN SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 437 SWEDEN PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 438 SWEDEN BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 439 SWEDEN BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 440 SWEDEN OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 441 SWEDEN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 442 SWEDEN BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 443 SWEDEN SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 444 SWEDEN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 445 SWEDEN PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 446 SWEDEN TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 447 SWEDEN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 448 SWEDEN BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 449 SWEDEN SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 450 SWEDEN SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 451 SWEDEN GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 452 SWEDEN ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 453 SWEDEN SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 454 SWEDEN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 455 SWEDEN RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 456 POLAND SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 457 POLAND MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 458 POLAND ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 459 POLAND CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 460 POLAND ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 461 POLAND ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 462 POLAND ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 463 POLAND CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 464 POLAND CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 465 POLAND OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 466 POLAND SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 467 POLAND PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 468 POLAND BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 469 POLAND BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 470 POLAND OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 471 POLAND SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 472 POLAND BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 473 POLAND SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 474 POLAND SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 475 POLAND PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 476 POLAND TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 477 POLAND SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 478 POLAND BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 479 POLAND SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 480 POLAND SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 481 POLAND GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 482 POLAND ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 483 POLAND SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 484 POLAND SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 485 POLAND RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 486 NORWAY SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 487 NORWAY MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 488 NORWAY ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 489 NORWAY CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 490 NORWAY ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 491 NORWAY ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 492 NORWAY ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 493 NORWAY CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 494 NORWAY CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 495 NORWAY OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 496 NORWAY SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 497 NORWAY PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 498 NORWAY BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 499 NORWAY BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 500 NORWAY OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 501 NORWAY SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 502 NORWAY BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 503 NORWAY SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 504 NORWAY SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 505 NORWAY PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 506 NORWAY TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 507 NORWAY SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 508 NORWAY BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 509 NORWAY SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 510 NORWAY SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 511 NORWAY GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 512 NORWAY ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 513 NORWAY SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 514 NORWAY SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 515 NORWAY RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 516 FINLAND SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 517 FINLAND MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 518 FINLAND ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 519 FINLAND CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 520 FINLAND ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 521 FINLAND ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 522 FINLAND ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 523 FINLAND CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 524 FINLAND CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 525 FINLAND OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 526 FINLAND SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 527 FINLAND PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 528 FINLAND BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 529 FINLAND BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 530 FINLAND OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 531 FINLAND SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 532 FINLAND BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 533 FINLAND SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 534 FINLAND SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 535 FINLAND PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 536 FINLAND TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 537 FINLAND SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 538 FINLAND BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 539 FINLAND SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 540 FINLAND SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 541 FINLAND GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 542 FINLAND ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 543 FINLAND SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 544 FINLAND SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 545 FINLAND RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 546 REST OF EUROPE SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
Liste des figures
FIGURE 1 EUROPE SJS/TEN TREATMENT MARKET: SEGMENTATION
FIGURE 2 EUROPE SJS/TEN TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE SJS/TEN TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 EUROPE SJS/TEN TREATMENT MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE SJS/TEN TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE SJS/TEN TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE SJS/TEN TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE SJS/TEN TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 EUROPE SJS/TEN TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE SJS/TEN TREATMENT MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE AND INCIDENCE OF SJS/TEN ARE EXPECTED TO DRIVE THE EUROPE SJS/TEN TREATMENT MARKET IN THE FORECAST PERIOD FROM 2023 TO 2030
FIGURE 12 THE MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE SJS/TEN TREATMENT MARKET IN THE FORECAST PERIOD OF 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE SJS/TEN TREATMENT MARKET
FIGURE 14 EUROPE SJS/TEN TREATMENT MARKET: BY TREATMENT, 2022
FIGURE 15 EUROPE SJS/TEN TREATMENT MARKET: BY TREATMENT, 2023-2030 (USD MILLION)
FIGURE 16 EUROPE SJS/TEN TREATMENT MARKET: BY TREATMENT, CAGR (2023-2030)
FIGURE 17 EUROPE SJS/TEN TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 18 EUROPE SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, 2022
FIGURE 19 EUROPE SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, 2023-2030 (USD MILLION)
FIGURE 20 EUROPE SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, CAGR (2023-2030)
FIGURE 21 EUROPE SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, LIFELINE CURVE
FIGURE 22 EUROPE SJS/TEN TREATMENT MARKET: BY CAUSE, 2022
FIGURE 23 EUROPE SJS/TEN TREATMENT MARKET: BY CAUSE, 2023-2030 (USD MILLION)
FIGURE 24 EUROPE SJS/TEN TREATMENT MARKET: BY CAUSE, CAGR (2023-2030)
FIGURE 25 EUROPE SJS/TEN TREATMENT MARKET: BY CAUSE, LIFELINE CURVE
FIGURE 26 EUROPE SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 27 EUROPE SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
FIGURE 28 EUROPE SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 29 EUROPE SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 30 EUROPE SJS/TEN TREATMENT MARKET: BY DRUG TYPE, 2022
FIGURE 31 EUROPE SJS/TEN TREATMENT MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION)
FIGURE 32 EUROPE SJS/TEN TREATMENT MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 33 EUROPE SJS/TEN TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 34 EUROPE SJS/TEN TREATMENT MARKET: BY THERAPY AREA, 2022
FIGURE 35 EUROPE SJS/TEN TREATMENT MARKET: BY THERAPY AREA, 2023-2030 (USD MILLION)
FIGURE 36 EUROPE SJS/TEN TREATMENT MARKET: BY THERAPY AREA, CAGR (2023-2030)
FIGURE 37 EUROPE SJS/TEN TREATMENT MARKET: BY THERAPY AREA, LIFELINE CURVE
FIGURE 38 EUROPE SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, 2022
FIGURE 39 EUROPE SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, 2023-2030 (USD MILLION)
FIGURE 40 EUROPE SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, CAGR (2023-2030)
FIGURE 41 EUROPE SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 42 EUROPE SJS/TEN TREATMENT MARKET: BY END USER, 2022
FIGURE 43 EUROPE SJS/TEN TREATMENT MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 44 EUROPE SJS/TEN TREATMENT MARKET: BY END USER, CAGR (2023-2030)
FIGURE 45 EUROPE SJS/TEN TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 46 EUROPE SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 47 EUROPE SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 48 EUROPE SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 49 EUROPE SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 50 EUROPE SJS/TEN TREATMENT MARKET: SNAPSHOT (2022)
FIGURE 51 EUROPE SJS/TEN TREATMENT MARKET: BY COUNTRY (2022)
FIGURE 52 EUROPE SJS/TEN TREATMENT MARKET: BY COUNTRY (2023 & 2030)
FIGURE 53 EUROPE SJS/TEN TREATMENT MARKET: BY COUNTRY (2022 & 2030)
FIGURE 54 EUROPE SJS/TEN TREATMENT MARKET: BY TREATMENT (2023-2030)
FIGURE 55 EUROPE SJS/TEN TREATMENT MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
